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Abstract
Pneumonia is one of the most common infectious diseases and the fourth leading 
cause of death globally. According to US statistics in 2019, pneumonia is the most 
common cause of sepsis and septic shock. In the US, inpatient pneumonia hospital-
izations account for the top 10 highest medical costs, totaling $9.5 billion for 960,000 
hospital stays. The emergence of antibiotic resistance in the treatment of infectious 
diseases, including the treatment of pneumonia, is a globally alarming problem. 
Antibiotic resistance increases the risk of death and re-hospitalization, prolongs 
hospital stays, and increases treatment costs, and is one of the greatest threats in 
modern medicine. Drug-related problems (DRPs) in pneumonia - such as suboptimal 
antibiotic indications, prolonged treatment duration, and drug interactions - increase 
the rate of antibiotic resistance and adverse effects, thereby leading to an increased 
burden in treatment. In a context in which novel and effective antibiotics are scarce, 
mitigating DRPs in order to reduce antibiotic resistance is currently a prime concern. 
A variety of interventions proven useful in reducing DRPs are antibiotic stewardship 
programs, the use of biomarkers, computerized physician order entries and clinical 
decision support systems, and community-acquired pneumonia scores.
Keywords: Pneumonia, drug-related problems, re-hospitalization, prescriptions, 
interventions
1. Introduction
Pneumonia is an acute lower respiratory tract infection caused by bacteria, 
viruses, or fungi. Groups of patients at high risk of getting pneumonia include 
children under 5 years old, people over 65 years old, and people with comorbidities. 
Pneumonia is the leading cause of death in children, and among the top four causes 
of death globally [1]. Each year, pneumonia kills more than 800,000 children under 
the age of 5, equivalent to about 2,200 children every day [2]. In the United States, 
the annual incidence of community-acquired pneumonia (CAP) was 248 cases per 
100,000 persons [3]. A study in central Vietnam reported that the incidence of CAP 
Pneumonia
2
in subjects aged ≥ 65 years was 4.6 per 1,000 person-years (95% CI, 3.8–5.5) [4]. 
Hospitalized patients diagnosed with pneumonia accounted for 19.9%, 6.4%, and 
1.5% in the Philippines, Malaysia, and Indonesia, respectively. The total esti-
mated costs incurred for pneumonia patients were in Malaysia 4.1 million USD, in 
Indonesia 2.6 million USD, and in the Philippines 2.6 million USD [5].
Drug-related problems are defined as ‘events or circumstances involving drug 
therapy that actually or potentially interfere with desired health outcomes’ [6]. 
Causes of DRPs can be related to inappropriate drug selection, inappropriate dos-
age, duration of use of medication longer or shorter than recommended, incorrect 
drug use processes, or poor compliance, all resulting in decreased treatment effec-
tiveness and increased morbidity and mortality [7–9]. In Ethiopia, the proportion 
of patients hospitalized for infectious diseases, and who also had DRPs, was 71.51% 
(123/172); of these, the unnecessary broad-spectrum antibiotic option ceftriaxone 
accounted for 44.77% [10]. Similarly, in a study in Spain, almost half (45.1%) of 
hospitalized patients suffered from DRPs [11]. Common DRPs associated with 
pneumonia include inappropriate antibiotic indications, prolonged antibiotic 
treatment, and overtreatment, which may lead to potential drug–drug interactions 
[12–15]. In the context of increasing antibiotic resistance, prescribing doctors, often 
concerned about possibly missing pathogenic bacteria, tend to prescribe broad-
spectrum antibiotics over a longer treatment time to avoid recurrence of the disease. 
Fear, rather than lack of knowledge, is a major barrier to preventing overtreatment 
with antibiotics [16]. Therefore, a new method being considered for improving 
empirical antibiotic selection is the community-acquired pneumonia score. This 
score can be used in a prediction model of clinical data, enabling more accurate 
application of empirical antibiotics [17]. In addition, many intervention tools need 
to be applied, such as antibiotic management programs, biomarkers, and comput-
erized physician order entries (CPOE), to ensure the effectiveness and safety of 
guideline compliance. The computerized physician order entry (CPOE) and clinical 
decision support systems (CDSS) are valuable technological tools for use in inter-
ventions to prevent adverse drug events (ADEs). However, in the healthcare system, 
the role of the clinical pharmacist in minimizing DRPs remains crucial [14]. The 
chapter is, therefore, to summarize an overview of DRPs in pneumonia and recom-
mend some strategies for reducing these DRPs.
2. Drug-related problems in pneumonia
2.1 Improper drug selection and dose selection
Prescribing inappropriate antibiotics leads to increased mortality, the develop-
ment of antimicrobial resistance, and added treatment costs [18, 19]. Meta-analysis 
of 7401 patients with ventilator-associated pneumonia (VAP), using unadjusted 
data, revealed that inappropriate antibiotic therapy significantly increased the mor-
tality of patients (odds ratio [OR], 2.34; 95% CI, 1.51–3.63; P = 0.0001, I2 = 28.5%) 
[8]. A retrospective cohort study of bacteremic pneumonia, conducted in Barnes-
Jewish Hospital in Missouri, USA (2008–2015) using multivariable logistic regres-
sion analysis for hospital mortality, indicated that inappropriate initial antibiotic 
treatment had the greatest odds ratio with mortality (OR 2.2, 95% CI 1.5–3.2, 
P < 0.001). The rate of inappropriate antibiotic initiation was significantly higher 
in patients with ceftriaxone-resistant pathogens than with ceftriaxone-susceptible 
pathogens (27.9% vs. 7.1%, P < 0.001), and the associated hospital mortality rates 
were respectively 41.5% vs. 32.0% (P = 0.001) [9].
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Inappropriate antibiotic selection is one of the most common DRPs in patients 
with pneumonia, and particularly community-acquired pneumonia (CAP). 
Antibiotic prescriptions collected from 22 pharmacies in Mongolia indicated 
that inappropriate drug selection affected both adults (57.7%) and children 
(56.6%) [20]. A study among 518 outpatients with CAP in the Veterans Affairs 
Western New York Healthcare System indicated that 69% of patients received 
an inappropriate antibiotic; for 76.7% of them an incorrect drug had been 
prescribed, based on the patient’s comorbidities [21]. In Thailand, a prospective 
observational study of severe CAP in general medical wards showed that 52% of 
patients received initial antibiotic regimens that were discordant with IDSA/ATS 
guidelines [22].
The increase in resistance rates of bacteria to antibiotics leads to inappropriate 
selection of initial antibiotics. Due to an “encirclement” mentality, doctors often 
tend to choose empiric broad-spectrum antibiotics; this invisible cause increases 
antibiotic resistance, resulting in a “vicious circle” that increasingly burdens 
patients and society [23–25]. In particular, prescribing broad-spectrum antibiotics 
for a low-risk group increases the risk of unwanted effects rather than making treat-
ment beneficial. According to current guidelines for the treatment of community-
acquired pneumonia, an outpatient should receive beta-lactam or a macrolide or 
doxycycline [26, 27]. A retrospective chart review at a large hospital indicated 
that fluoroquinolones were antibiotics overprescribed for 71% of patients in the 
low-risk group [28]. Another retrospective chart review among 156 adult patients 
with a diagnosis of CAP, admitted to a community hospital emergency department 
in Canada, found that physicians overprescribed fluoroquinolones for 80.8% of 
patients who did not need them [29]. Over-prescribing of fluoroquinolones for 
outpatients with pneumonia increases the risk of side effects: tendon rupture, 
tendonitis, feeling shaky, unusual hunger, serious events of aortic ruptures or tears, 
and development of antibiotic resistance [30–32].
For this reason, antibiotic stewardship programs (ASPs) and clinical pharma-
cists play an important role in promoting the appropriate prescribing of empiric 
antibiotics. A retrospective cohort study of patients with CAP indicated a  
significant reduction in fluoroquinolone prescribing over time following inter-
vention involving ASPs and clinical pharmacists [33]. An additional new method 
for improving empirical antibiotic selection is the community-acquired pneu-
monia score. This score provides a model of clinical data, thereby enabling the 
proper use of empirical antibiotics [17]. Implementation of an empiric therapy 
guide is important to minimize DRPs in the initial selection of antibiotics for 
pneumonia, as the causative organism and the patient’s susceptibility to it are 
often unknown at the time of prescription. Galanter KM et al. demonstrated 
that after intervention in accordance with the empiric therapy guide, the rate 
of broad-spectrum antibiotic indication for CAP decreased significantly, by 
17.0% [34].
In Canada, a study on pneumonia showed that prescribed antibiotic doses 
tended to be higher than recommended [29]. In contrast, a prospective multina-
tional study involving 68 ICUs across 10 countries confirmed that 20% of patients 
received less than the most conservative PK/PD target (50% f T > MIC), and 
fewer than 50% of patients received a preferred PK/PD target (100% f T > MIC) 
[13]. Such insufficient antibiotic exposure can also facilitate antibiotic resistance. 
For the treatment of CAP, especially critical patients require individualized dos-
ing based on the severity of disease, local documented pathogen susceptibilities, 





Pneumonia patients often have not just one diagnosis but suffer from comorbid 
conditions. Frequent comorbidities are diabetes mellitus, cerebrovascular disease, 
chronic lung disease, chronic kidney disease, and dementia [15, 35, 36]. Common 
medication classes used for the management of comorbid conditions are cardio-
vascular agents, alimentary tract and metabolism agents, nervous system agents, 
respiratory agents, blood-forming agents, and general anti-infective agents for sys-
temic use. The potential of drug–drug interactions in cases of pneumonia is more 
prevalent in older patients, possibly leading to chronic diseases and polypharmacy; 
some drugs even increase the risks of pneumonia [37]. In pneumonia patients, 
comorbidities have been strongly associated with long-term mortality [36], and 
concurrent use of multiple drugs can lead to an increased risk of drug–drug interac-
tions (DDIs) [15, 35, 38]. Results of a study in a population, most of whom were 
concurrently using >10 drugs, revealed that 73.1% of these patients faced potential 
DDIs. Indeed, more than half of the patients presented with major potential DDIs 
[15]. Furthermore, nearly 75% of patients with community-acquired pneumonia 
(CAP) were subjected to polypharmacy [35].
Some clinical consequences of DDIs included increased or decreased therapeutic 
effectiveness, adverse drug reactions (ADRs), and toxicity (nephrotoxicity, hepa-
totoxicity) [15, 38]. DDIs can take place between different antibiotics, and between 
antibiotics and other medications. For treating pneumonia many guidelines 
recommend using β-lactams, macrolides, and fluoroquinolones. This may cause a 
prolonged QT interval (when fluoroquinolones or macrolides are administered) 
or a prolonged Prothrombin Time and International Normalized Ratio (INR) (if 
fluoroquinolones and warfarin are administered concurrently) [37]. Therefore, 
to prevent the negative effects of polypharmacy, consultations should be held to 
identify potential DDIs and alert physicians. Moreover, medical staff should refer 
to more than one drug interaction checker tool -- like Lexi-Interact, Micromedex, 
Medscape, Drugs.com. -- as well as adhere to guidelines for optimizing the use of 
prescribed drugs and discontinuing the use of unnecessary drugs.
2.3 Initiation and duration of administration antibiotic treatment
Patients whose initial appropriate antibiotics therapy is delayed may have 
increased morbidity rates compared to those receiving appropriately prescribed 
therapy on time. A systematic review in patients hospitalized with infections due to 
Klebsiella pneumoniae or Escherichia coli found that a delay in appropriate antibiotic 
therapy of more than 24 hours and 48 hours after culture collection, or in culture 
and susceptibility reporting, can increase the risk of mortality: OR 1.60 (95% 
CI, 1.25–2.50) and OR 1.76 (95% CI, 1.27–2.44) respectively [39]. A prospective 
cohort study in patients with VAP showed that for thirty-three patients (30.8%) the 
appropriate antibiotic treatment was delayed for >24 hours after they first met the 
diagnostic criteria for VAP; this initially delayed appropriate antibiotic treatment 
was a risk factor for increasing the hospital mortality rate (adjusted odds ratio, 7.68; 
95% CI 4.50 to 13.09; p < 0.001) [40].
The British Thoracic Society Guidelines for the Management of Community-
Acquired Pneumonia in Adults recommends the administration of antibiotics 
within four hours of admission to hospital for adults with radiologically confirmed 
CAP [41]. A large study (n = 13,725 from 188 institutions) conducted among adults 
hospitalized with CAP indicated that 37% of patients failed to receive antibiotics 
within four hours of admission. Delay time of the first antibiotic was associated 
with a greater OR of 30-day inpatient mortality. The adjusted 30-day inpatient 
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mortality was lower for adults who received their initial antibiotic within four 
hours, compared with >4 hours (adjusted OR 0.84, 95% CI 0.74 to 0.94; p = 0.003) 
[42]. A retrospective study (n = 18,209) of Medicare patients older than 65 years 
who were hospitalized with CAP revealed that 39.1% did not receive antibiotics 
within four hours of admission. Initial administration of antibiotics within four 
hours, versus more than four hours, after arrival at the hospital was associated with 
reduced in-hospital mortality (6.8% vs. 7.4%; adjusted odds ratio (AOR)), 0.85; 
95% CI, 0.74–0.98), versus mortality within 30 days of admission (11.6% vs. 12.7%; 
AOR, 0.85; 95% CI, 0.76–0.95), and length of stay exceeding the 5-day median 
(42.1% vs. 45.1%; AOR, 0.90; 95% CI, 0.83–0.96) [43].
For a long time, a seven-day application of antibiotic therapy to treat infec-
tious diseases was standard procedure [44]. However, the duration of antibiotic 
treatment should be based on the severity of the disease, patient characteristics, 
patients’ clinical stability, and the causative organisms [45]. Long-term antibiotic 
treatment is associated with increased side- effects, antibiotic-resistant organisms, 
and C. difficile diarrhea [46, 47]. Unfortunately, a large study in 66,901 long-term 
care residents showed that 44.9% of patients were prescribed antibiotic treatment 
lasting longer than 7 days, and prescriptions tended not to be based on patient 
characteristics and comorbidities [14]. Furthermore, a retrospective cohort of 
152,874 patients hospitalized for CAP found that more than 70% were prescribed 
antibiotics in excess of recommendations [48]. A large US study found that for 
93% and 71% of patients with uncomplicated CAP and healthcare-associated 
pneumonia, respectively, lengthy durations of antibiotic treatment were indi-
cated [49].
In addition, a systematic review of HAP in critically ill adults (including VAP) 
manifested that a short duration of antibiotic therapy (7 to 8 days) versus conven-
tional antibiotic therapy (10 to 15 days) did not increase mortality rate, duration of 
mechanical ventilation, and length of hospital stay; however, a rise in recurrence 
was discovered in the subgroup of patients with VAP, caused by non-fermenting 
Gram-negative bacilli [50]. An RCT study in neonatal pneumonia conducted to 
compare the efficacy of a short course (4 days, intervention group) with a tradi-
tional antibiotic regimen (7 days, control group) demonstrated that treatment in 
the intervention group had the same success rate as in the control group, but the 
group intervention significantly reduced the length of the hospital stay, as well as 
antibiotic use and treatment costs [51].
For adults with CAP, although more relevant antibiotic studies are needed in the 
future to support a short-term therapy, clinicians should always be aware that the 
duration of antibiotic treatment should be based on the clinical improvement of  
the patient rather than mechanical practice. ATS/IDSA guidelines recommend a 
total duration of antibiotic therapy of 5 days for most outpatients and inpatients 
with CAP, except for cases of suspected MRSA or P. aeruginosa. According to the 
guidelines, the patient will achieve clinical improvement after the first 48–72 hours, 
after which antibiotics should be continued for 2–3 days [45]. Pending further  
studies, adherence to guidelines is one of the keys to limiting DRPs in treatment.
For pediatric patients with CAP, according to the 2011 PIDS/IDSA guidelines, 
which are still applicable today, the duration of treatment depends upon the sever-
ity. Treatment courses of 10 days are recommended, although the guidelines suggest 
that shorter courses may be just as effective, especially in mild patients. CA-MRSA 
patients may need a longer treatment period [26].
For adults with HAP/VAP, although the duration of antibiotic use is determined 
based on patients’ conditions like a clinical improvement, as well as radiological and 
laboratory parameters, the current recommendation for most patients is a 7-day 
course of antimicrobial therapy rather than longer treatment [52].
Pneumonia
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In conclusion, the high rate of prolongation of antibiotic treatment and inap-
propriate initiation of therapy in patients with pneumonia indicates the great need 
for improvement to reduce drug-related problems. Antimicrobial stewardship, 
biomarkers, and clinical stability scores should be applied to decrease the duration 
of antibiotic therapy [53, 54].
2.4 Comorbidities
Respiratory diseases have been found to be associated with multi-morbidity 
patterns [55]. Patients with pneumonia often have a broad range of comorbid 
conditions [37, 56]. While short-term mortality is directly associated with the 
severity of pneumonia, long-term mortality is associated with comorbid condi-
tions [56]. Most patients who die from pneumonia have one or more severe 
chronic diseases, such as cerebrovascular disease, chronic cardiac or renal disease, 
dementia, cachexia, mobility impairment, neoplastic metastatic disease, or sepsis. 
Patients with either MRSA or Pseudomonas were found to have an increased risk 
of dying of pneumonia [57]. In patients with pneumonia, comorbidities are also 
associated with poor response to treatment. Moreover, patients older than 80 years 
with comorbidities also have a higher mortality rate than patients from other age 
groups [58].
All-cause mortality has been found to increase in relation to the number of 
comorbid conditions. Every comorbid condition has been found to correlate with 
a 9% higher risk of death [56]. Some comorbid conditions that influence mortality 
(cardiovascular and lung diseases, diabetes, etc.) are also particular risk factors for 
pneumonia [37].
The Charlson Comorbidity Index measures comorbidity. Patients with a higher 
Charlson pathology index score were found to have a higher risk of death due to 
hospitalization (OR 1.28; 95% CI 1.07–1.53). These findings indicate a relationship 
between a patient’s comorbid burden and the consequences of community-acquired 
pneumonia [59]. Results of a study among 108 patients by Franzen et al. indicated 
that the death risk of hospitalized pneumonia patients tended to increase with a 
higher CCI [58].
Children with comorbidities were more likely to be hospitalized for community-
acquired pneumonia, compared to those without comorbidities. Approximately 
50% of children and adolescents with community-acquired pneumonia had comor-
bidities related to malnutrition, as well as the use of antibiotics and hospitalization 
for community-acquired pneumonia during the previous 24 months. Bivariate 
analysis showed that patients with comorbidities demonstrated higher chances of 
malnutrition (p = 0.002), previous use of antibiotics (p = 0.008), and previous hos-
pitalization for community-acquired pneumonia in the last 24 months (p = 0.004). 
In multivariate analysis, the following variables were independent predictors of 
community-acquired pneumonia in patients with comorbidities: malnutrition 
(p = 0.008; RR = 1.75; 95%CI 1.75–44.60); previous use of antibiotics (p = 0.0013; 
RR = 3.03; 95%CI 1.27–7.20); and previous hospitalization for community-acquired 
pneumonia (p = 0.035; RR = 2.91; 95%CI 1.08–7.90) [60].
In addition, pneumonia influenced concurrent comorbid conditions, resulting 
in a subsequent impact on the incidence of events like acute myocardial infarction, 
heart failure, stroke, venous thromboembolism, and cancer [56]. Recognition of 
the mutual relationship between pneumonia and comorbidities will help to identify 
patients at high risk. Though no specific guideline for multi-morbidities currently 
exists, close monitoring of patients during hospitalization and long-term follow-up 
may result in better outcomes.
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2.5 Risk factors for DRP-readmission and pneumonia re-hospitalization
According to a review on drug-related hospital readmissions, an average of 21% 
of such readmissions were drug-related, and 69% were considered preventable 
[61]. Some predictive factors that can be considered to avoid hospital readmissions 
due to DRPs include limiting the number of drugs prescribed on a particular day, 
and the number of drug classifications according to the day of hospitalization [62]. 
Healthcare professionals should focus more on identifying risk factors related to 
drug-related readmissions, and on finding appropriate interventions.
Among the known risk factors for DRPs is non-adherence to medication, which 
may be aggravated by the complexity of the medication regimen. The medica-
tion regimen complexity index (MRCI) is a tool that assesses the complexity of a 
medication list in terms of dosage form, dosing frequency, and additional directions 
required for administration. Higher MRCI scores indicate greater regimen complex-
ity. MRCI scores were significantly higher in patients readmitted (within 30 days) 
than those not readmitted [63, 64]. The MRCI can thus be used as a predictor of 
drug-related readmissions.
Another risk factor associated with 30-day readmission rates was the presence 
of comorbidities [65]. Comorbidities weaken the immune system and worsen a 
patient’s condition. The Charlson Comorbidity Index (CCI) is a tool that adds 
weighted scores to each illness predictive of mortality. Some studies have reported a 
higher mean CCI in patients who were re-admitted [62, 65]. As the CCI apparently 
has a strong potential to be a readmission predictor, it has been recommended for 
inclusion in readmission prediction tools [63].
Risk factors for pneumonia re-hospitalization are currently among the most 
important problems to be dealt with. Possible risk factors for early re-hospitaliza-
tions include male gender, age ³ 70 years, the longer length of stay during the first 
admission, and a Multisource Comorbidity Score (MCS) ³ 10. As for therapy, for 
readmitted CAP patients whose underlying respiratory disease has not yet been 
determined, the value of inhaled therapy has not definitely been decided. “Inhaled 
steroids may favor CAP in COPD patients, whereas anticholinergics may favor CAP 
in asthma patients. It is difficult to differentiate the effect of inhaled therapy from 
the effect of COPD or asthma severity on the risk of CAP, and these relationships 
may not be causal, but could call attention to inhaled therapy in COPD and asthma 
patients.” [66]. In pediatric patients infected with Mycoplasma pneumonia, read-
mission before 90 days after discharge is influenced by age, body temperature, and 
influenza A co-infection during hospitalization [67]. However, in adult patients, 
risk factors for readmission within 30 days after hospital discharge include the 
person’s age, hospitalization frequency during 3 months, chronic respiratory  
failure, heart failure, chronic liver disease, and the (non)availability of home 
healthcare [68].
A post-discharge study was performed in which researchers phoned every 
patient within 48–96 hours after they left the hospital to ask about their medica-
tion adherence, any adverse drug events (ADEs), and their use of medication. The 
process of medication reconciliation identified 103 errors, or 2.4 errors per patient, 
especially errors related to inaccurate doses, frequency, or medications not included 
on the list of home medications (Table 1) [69].
Multivariable analysis showed pneumonia-related readmission to be connected 
to para/hemiplegia, malignancy, pneumonia severity index class ≥4, and clinical 
instability ≥1 upon hospital discharge. Comorbidities such as chronic lung disease 
and chronic kidney disease, treatment failure, and decompensation of comorbidities 
were correlated with the pneumonia-unrelated 30-day re-hospitalization rate [65].
Pneumonia
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3. Strategies for reducing DRPs in pneumonia
3.1 Role of a clinical hospital pharmacist in patient care
Various interventions are needed, focused on reducing the risk of hospital 
readmissions by choosing transitional and territorial care and synchronizing 
post-discharge care [66]. Pharmacist-bundled interference was associated with 
a decline in the 30-day readmission rate for high-risk patients with pneumonia. 
Consequently, reducing hospital readmissions by supplying the greatest possible 
quality of health care is now becoming an essential consideration, also for the 
institutions themselves [69]. Also, identifying drug-resistant pathogens in pneu-
monia patients may help to determine the appropriate choice of empirical antibiot-
ics. Further, building a model to define the patient’s risk factors may help with the 
prescription of broad-spectrum antibiotics [70]. Antibiotic administration for 
outpatients can be improved by predicting factors related to inappropriate antibi-
otic regimens. Patients at risk of drug resistance are now among the predictors of 
unsuitable antibiotic regimens [21].
The outcomes of this pilot research show that a pharmacist-specific bundled 
intervention, involving medication reconciliation, curative advice, patient 
discharge direction, and a research phone call, was associated with a decreased 
30-day readmission rate for high-risk patients with pneumonia. The more than 
200 total interventions reported suggest countless promising opportunities for 
increased pharmacist participation in care. Permitting pharmacists to devote time 
and effort to high-risk patient populations could confirm their value in supporting 
and expanding services to other people in the future, as well as reduce health care 
prices, and eventually the extent of welfare patient care [69].
Interventions (n = 186) n (%)
Medication reconciliation (n = 103)
Incorrect dose or frequency 49 (48)
Medication omitted 33 (32)
Medication added 14 (14)
Duplicate therapy 4 (4)
Counseled in nonadherence 3 (3)
Mean errors per patienta 2.4
Therapeutic recommendations (n = 38)
Change route 29 (76)
Optimize therapy 7 (18)
De-escalate therapy 2 (5)
Discharge counseling (n = 45)
Counseling on antibioticsb 33 (73)
Counseling on chronic medication changes 12 (27)
Note: All data are given as n (%) unless otherwise specified, and all percentages are rounded to the nearest whole 
number.
an = 43 patients.
bn = 39 patients were prescribed discharge antibiotics.
Table 1. 
Medication errors identified, and pharmacist interventions.
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Modifying the route of administration (ex- or intravenous to oral) was the most 
popular intervention, second to optimizing therapy. Optimizing therapy included 
making suitable renal doses and suggesting substitute regimens, especially if a 
patient’s inpatient antibiotic regimen was the same as an outpatient regimen that 
had failed, or if he or she had risk factors for a healthcare-associated infection. 
Regarding the element of discharge counseling in the intervention, 91% of patients 
chosen prospectively for a pilot study received such counseling. This single-center 
pilot research concentrated on the influence pharmacists can have on transitions 
of care and readmission rates, using interventions like medication reconciliation, 
therapeutic recommendations, discharge instructions, and follow-up [66].
3.2 Antibiotic stewardship programs
J.E. McGowan Jr. and D.N. Gerding were the first to create the term “antimi-
crobial stewardship” in an article published in 1996. They wanted to emphasize 
the need for appropriate antibiotic prescription in order to prevent resistance [71]. 
IDSA defined these as “antibiotic stewardship programs referring to coordinated 
interventions designed to improve and measure the appropriate use of antimicro-
bial agents” [72]. The 5 “Rs” of anti-microbial stewardship are: “the right drug at 
the right time with the right dose for the right bug for the right duration” [16]. The 
goals of ASP increase treatment effectiveness while reducing C. difficile infections, 
adverse effects, antibiotic resistance, hospital costs, and lengths of stay. Some 
activities related to antibiotic stewardship in CAP include monitoring the de-esca-
lation and duration of antibiotic treatment, complying with treatment guidelines, 
switching from intravenous to oral antibiotic treatments, prospective auditing, and 
developing the multidisciplinary team [73]. Antibiotic stewardship contributes to 
rational prescription of antibiotics, increases treatment effectiveness, and reduces 
side-effects and antibiotic resistance. A multi-center, pre-empirical, quasi-
experimental study including 600 CAP patients (307 in the historical control group 
and 293 in the stewardship intervention group) showed that antibiotic stewardship 
helped to increase guideline-concordance to the duration of antibiotic therapy 
from 5.6% in the historical group to 42% in the intervention group (P = 0.001). 
The intervention group received a significantly shorter mean duration of treat-
ment than the historical group (6 (5–7) versus 9 (7–10) days, P = 0.001). Antibiotic 
stewardship helped to avoid a total of 586 days of unnecessary antibiotics during 
the 6-month intervention period, while incidence of readmission for CAP, mortality 
rate within 30 days post-discharge were similar in both groups [54]. A multicenter 
randomized trial including 312 hospitalized CAP patients found that the duration 
of antibiotic therapy as determined by the physician (control group) was longer 
than in the guideline-concordant group (intervention group): (median, 10 days 
[interquartile range, 10–11]) versus 5 days (interquartile range, 5–6.5), respectively; 
P < .001). Clinical success was similar between both groups, at both 10 days (48.6% 
versus 56.3%) and 30 days (88.6% versus 91.9%) after admission [73].
The major activities and elements of ASPs include [74]:









Hospital Leadership Commitment: The senior leadership of the hospital, 
especially the chief medical officer, plays an important role in the success of ASPs. 
Hospital leadership helps to provide ASPs with the resources needed to achieve 
their goals.
Accountability: ASPs must have a designated leader or co-leaders, such as a 
physician and pharmacist, who have effective leadership, management, and com-
munication skills, and are responsible for program management and outcomes.
Pharmacy Expertise: The participation of pharmacists, ideally as co-leaders 
of ASPs, will help to make ASPs highly effective. In large hospitals, pharmacists 
with infectious disease training are designated, but in hospitals without infectious 
disease trained pharmacists, general clinical pharmacists are appointed to help lead 
implementation efforts to improve antibiotic use.
Action: Antibiotic stewardship interventions are initiated to improve antibiotic 
use. Some activities related to antibiotic stewardship in CAP include prospective 
audit and feedback, such as monitoring the de-escalation and duration of antibiotic 
treatment, complying with treatment guidelines, switching from intravenous to 
oral antibiotic treatments, and preauthorization. The three priority interventions 
are: prospective audit and feedback, preauthorization, and facility-specific treat-
ment guidelines.
• Preauthorization: This requires prescribers to gain approval prior to the use 
of certain antibiotics. This can help to optimize initial empiric therapy. The 
development of preauthorization for necessary antibiotics can be based on 
standard guidelines; limited antibiotics can be prescribed based on consulta-
tion, or more easily, referring to the WHO antibiotic classification. In 2017, 
WHO proposed categorizing antibiotics into three groups: ACCESS, WATCH, 
and RESERVE groups [75]. For the WATCH group, antibiotics with a high 
risk of resistance, such as 3rd-generation cephalosporins, carbapenems, and 
fluoroquinolones, should be preauthorized; for the RESERVE group, antibi-
otics such as colistin, ceftaroline, tigecycline, and aztreonam are indicated 
when other prescribed antibiotics have failed or are inadequate (e.g., serious 
life-threatening infections due to multidrug-resistant bacteria), and must be 
authorized and discussed before prescribing.
• Prospective audit and feedback: This is an external assessment of antibiotic 
therapy by ASP experts at some point after the agent has been prescribed. The 
ASP prospective audit and feedback team usually consists of a physician (an 
infectious disease specialist or a clinical microbiologist) and a clinical pharma-
cist. Prospective audit and feedback are performed as follows: On the first day 
of prescribed antibiotics, the team audits the suitability of doses and the routes 
of empirical antibiotic therapy. After 72 hours, the team reviews the patient’s 
response (clinical stability, biomarkers, renal function), along with micro-
biological culture results, to give feedback to the treating physician in case a 
need to change the therapy is indicated: change of antibiotic, the addition of 
antibiotic, de-escalation of antibiotic treatment, dose adjustment. The cycle 
of audit and feedback is performed continuously. On day 7, the team evaluates 
the duration of antibiotic treatment (Figure 1) [76]. Preauthorization and 
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prospective audit and feedback are complementary processes that optimize 
antibiotic therapy. Preauthorization resembles an antibiotic input “filter” that 
improves initiation of antibiotics, and prospective audit and feedback help to 
optimize continued therapy.
• Facility-specific treatment guidelines: A clear guideline on antibiotic use 
will help to make prospective audit and feedback easier and more effective. 
Recommendations should be developed based on national and international 
guidelines, local susceptibilities, and hospital antibiotic management policies.
Tracking: Measurement is crucial to identify opportunities for improvement 
and to assess the impact of interventions. Measurement of antibiotic stewardship 
interventions may include measures of antibiotic use, and measures of outcomes 
like C. difficile infections, antibiotic resistance, and financial impact.
Reporting: A comprehensive picture of antibiotic use and antibiotic resistance, 
along with the work of the antibiotic stewardship program, should be provided in 
regular updates to prescribers, pharmacists, nurses, and leadership. This helps make 
Figure 1. 
Schema for prospective audit and feedback, and formulary restriction and preauthorization, for ASPs.
Pneumonia
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medical staff aware of the situation of antibiotic use and antibiotic resistance at 
their facility, thereby promoting rational use of antibiotics.
Education: Interventions (preauthorization, prospective audit, and feedback) 
and measurement of antibiotic use and outcomes, can reveal gaps in antibiotic 
prescribing in hospitals. This helps to make the education of medical professionals 
realistic and effective, thereby gradually improving the effectiveness of antibiotic 
treatment, reducing adverse effects, antibiotic resistance, and treatment costs. 
There are many ways to provide education regarding antibiotic use, such as pre-
sentations; posters, flyers, and newsletters; and/or electronic communication to 
staff groups.
In summary, ASP interventions applied in hospitals, such as audit and feedback, 
updating of treatment guidelines along with local susceptibility patterns, and train-
ing of medical staff, can reveal individual or departmental cases of high antibiotic 
use by infectious disease specialists, clinical pharmacists, and microbiologists in 
order to promote rational antibiotic use [77].
3.3 Technological tools
3.3.1 Biomarkers
Among the oldest and most frequently used biomarkers for predicting a 
patient’s response to antibiotic therapy are fever and leukocytosis. A decline in 
both indicates that an infectious disease has been adequately treated with a chosen 
course of antibiotics. More recently, studies have shown that another biomarker, 
procalcitonin (PCT), can be combined with clinical criteria to help physicians to 
decide whether to de-escalate or discontinue antibiotic therapy, without affect-
ing outcomes [78]. A systematic review of 26 RCTs involving 6708 participants 
(acute respiratory infections) from 12 countries found that the duration of 
antibiotic therapy using PCT concentration reduced mortality, decreased antibi-
otic consumption, and lowered the risk of antibiotic side-effects. The length of 
hospital stay and ICU stay were similar in both groups [79]. A randomized trial 
of 621 patients with suspected community or hospital infection showed that the 
intervention group (using PCT) had a significantly shorter duration of antibi-
otic treatment than the control group (14.3 days (SD 9.1) vs. 11.6 days (SD 8.2); 
absolute difference 2.7 days, 95% CI 1.4 to 4.1, p < 0.0001) [80]. Similarly, an RCT 
of 101 patients with VAP indicated that antibiotic discontinuation based on serum 
PCT decreased their duration of antibiotic use compared with the control group 
(p  =  0.038) [81]. A novel multicenter quality control survey study, including 1759 
patients from Switzerland, France, and the United States who had respiratory 
tract infections, revealed that antibiotic therapy duration based on PCT concen-
tration was shorter than without PCT concentration (5.9 vs. 7.4 days; the abso-
lute difference in days (95% CI), −1.51 (−2.04 to −0.98); P < 0.001) [82]. The 
Infectious Diseases Society of America (IDSA) and the American Thoracic Society 
(ATS) suggest using PCT levels plus clinical criteria, rather than clinical criteria 
alone (weak recommendation, low-quality evidence), to guide discontinuation of 
antibiotic therapy [52].
Besides PCT, another biomarker useful in the management of pneumonia is 
C-reactive protein (CRP). Together with clinical criteria, low levels of CRP and 
PCT at 72 h of CAP treatment may improve the prognosis of an absence of severe 
complications [83]. In a study by Shuren Guo et al., performed on 350 hospitalized 
CAP patients, CRT and PCT levels on day 3 were statistically lower in the survivors 
compared to non-survivors [84]. The European Respiratory Society recommended 
that for patients with suspected pneumonia, along with observing clinical signs and 
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symptoms, a CRP test may be indicated. A CRP level of >100 mg/L, with symptoms 
for >24 hours makes pneumonia likely; a CRP level < 20 mg/L at presentation, with 
symptoms for >24 hours, is possibly caused by another respiratory tract infection [85].
Antibiotic resistance is one of the greatest threats to global health, and pneumo-
nia is one of several infections that are becoming less responsive to antibiotic treat-
ment. Antibiotic resistance increases the risk of mortality, prolongs hospital stays, 
and increases treatment costs. The unnecessary and prolonged use of antibiotics is 
an important cause contributing to the growth of multidrug-resistant bacteria [86]. 
This “one size fits all” approach can result in overtreatment, increased side effects, 
and antibiotic resistance. Therefore, individualization in treatment is important. In 
addition to clinical assessment, the physician may further consider assessing serum 
PCT and CRP levels to guide clinical decision-making.
3.3.2  Computerized provider order entry (CPOE) and clinical decision support 
system (CDSS)
Two useful tools which help in the prevention of ADEs are the computerized 
physician order entry (CPOE) and clinical decision support systems (CDSS). 
Compared with conventional medication control, the computerized alert system 
ADEAS selected different patients based on the risk of an ADE. For the hospital 
pharmacist, this makes ADEAS a valuable and appropriate tool in reducing the 
number of preventable ADEs [87].
The implementation of CPOE and advanced CDSS tools substantially increases 
the number of possible ADE alerts for pharmacist review, and the number of true-
positive ADE alerts per 1000 admissions [88].
In a statistical study involving 592 patients during the paper-based prescribing 
period and 603 patients in the CPOE/CDSS period, the total cost of the paper-based 
system was €12.37 per patient/day, and of CPOE/CDSS was €14.91 per patient/day. 
Incremental Cost-Effectiveness Ratios (ICER) for medication errors and for pre-
ventable adverse drug events were 3.54 and 322.70, respectively; this indicates the 
additional amount (€) necessary to prevent a medication error or an ADE. CPOE 
with primary CDSS contributes to the reduction of the risk of preventable harm. 
Overall, the additional CPOE/CDSS costs required to prevent medication errors or 
ADEs appear to be acceptable [89].
However, another study indicated a need to optimize the sensitivity of CPOE/
CDSS to detect certain classes of problems, because most DRPs identified by clinical 
pharmacists were not detected in daily clinical practice by CPOE/CDSS. This under-
lines the importance of the clinical pharmacist’s involvement to reduce DRPs [90].
4. Conclusion
Pneumonia is one of the respiratory diseases causing the highest mortality rate 
in children and the elderly. As the elderly often have many comorbidities, DRPs also 
greatly affect their condition and ability to recover.
DRPs in pneumonia are a very complex issue, requiring great attention from 
healthcare professionals and patients in prescribing, dispensing, and administering 
medications. Moreover, the rate of hospital readmissions for pneumonia is also a 
challenging burden, for the health system in general and for patients in particular. 
The application of technological tools such as CPOE and CDSS to prescribing and 
ordering can reduce the occurrence of DRPs, but it is physicians, clinical pharma-
cists and health professionals who play the most important role in reducing DRPs 
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